Celldex Therapeutics, Inc. - Common Stock (CLDX)

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.

CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%